September 30, 2020 by Jason Wertheimer Sonoma Bio named as one of most promising startups in biotech by Endpoints News Learn More
September 30, 2020 by Jason Wertheimer Jeffrey Bluestone recruits a trio of biopharma vets to the startup team at Sonoma — while adding $30M to the launch round Learn More
June 23, 2020 by Jason Wertheimer Foxp3: a genetic foundation for regulatory T cell differentiation and function Learn More
February 7, 2020 by Jason Wertheimer Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases Learn More
February 7, 2020 by Jason Wertheimer Parker Institute CEO Jeffrey Bluestone Steps Down to Launch Sonoma Biotherapeutics Learn More
February 6, 2020 by Jason Wertheimer Jeffrey Bluestone exits Parker and switches focus back to autoimmune diseases in cell therapy 2.0 launch Learn More